FTSE MIB
33.222,87 +35,98 (+0,11%) Dow Jones
39.164,06 +36,26 (+0,09%) Nasdaq
17.858,68 +53,53 (+0,30%) Nikkei 225
39.583,08 +241,54 (+0,61%) Petrolio
82,28 +0,54 (+0,66%) Bitcoin EUR
57.609,62 +411,38 (+0,72%)
Portage Biotech Inc. (PRTG)
Dopo ore:
| Chiusura precedente | 0,2210 |
| Aperto | 0,2218 |
| Denaro | 0,0000 x 0 |
| Domanda | 0,0000 x 0 |
| Min-Max giorno | 0,2180 - 0,2339 |
| Intervallo di 52 settimane | 0,2000 - 3,9500 |
| Volume | |
| Media Volume | 353.619 |
| Capitalizzazione | 4,471M |
| Beta (mensile su 5 anni) | 95,43 |
| Rapporto PE (ttm) | N/D |
| EPS (ttm) | -8,5200 |
| Prossima data utili | 29 lug 2024 - 02 ago 2024 |
| Rendimento e dividendo (futuro) | N/D (N/D) |
| Data ex dividendo | N/D |
| Stima target 1A | 7,00 |
GlobeNewswirePortage Biotech Announces $6.0 Million Registered Direct Offering
WESTPORT, Conn., Sept. 29, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that it has entered into a definitive agreement for the purchase and sale in a registered direct offering of an aggregate of 3,157,895 shares of its common stock (or common stock equivalents in lieu thereof), at a purchase price of $1.90 per share (or common stock equ
GlobeNewswirePortage Biotech to Participate in Panel Discussion at the Cantor Global Healthcare Conference
WESTPORT, Conn., Sept. 20, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as single agents and in combination, today announced that the Company’s management team will participate in a panel discussion at the Cantor Global Healthcare Conference on Thursday, September 28, 2023 at 10:20 – 10:50 AM ET in New York, NY. The Portage management team will participate in one-on-one investor meetings du
- GlobeNewswire
Portage Biotech Announces Collaboration with Merck to Evaluate Two Next-Generation Adenosine Antagonists in Combination with KEYTRUDA® (Pembrolizumab) in Solid Tumors
WESTPORT, Conn., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (NASDAQ: PRTG), a clinical-stage immuno-oncology company advancing novel multi-targeted therapies for use as monotherapy and in combination, today announced that it has entered into a clinical trial collaboration agreement with Merck (known as MSD outside the US and Canada) to evaluate Portage’s next-generation adenosine antagonists in combination with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 (programmed death receptor-
